High-sensitivity CRP reflects insulin resistance in smokers

Journal of Atherosclerosis and Thrombosis

Volumn 16, Issue 5, 2009, Pages 560-567

  Hanyu, Osamu ^a   Yoshida, Junko ^a   Abe, Eri ^a   Hirayama, Satoshi ^a   Miyake, Kazunori ^b   Aizawa, Yoshifusa ^a   Miida, Takashi ^b  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

High sensitivity C reactive protein (hs CRP); Homeostasis model assessment of insulin resistance (HOMA IR); Insulin resistance; Smoker

Indexed keywords

C REACTIVE PROTEIN; HEMOGLOBIN A1C;

ADULT; ANTHROPOMETRY; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; GLUCOSE TOLERANCE; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOREACTIVITY; INSULIN RESISTANCE; MALE; NORMAL HUMAN; PROTEIN BLOOD LEVEL; SMOKING; SYSTOLIC BLOOD PRESSURE;

EID: 73249133322     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.869     Document Type: Article

References (43)

1. Schultz DR, Arnold PI: Properties of four acute phase proteins: C-reactive protein, serum amyloid A protein, alpha 1-acid glycoprotein, and fibrinogen. Semin Arthritis Rheum, 1990; 20: 129-147
2. Li SP, Goldman ND: Regulation of human C-reactive protein gene expression by two synergistic IL-6 responsive elements. Biochemistry, 1996; 35: 9060-9068
3. Uhlar CM, Whitehead AS: Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem, 1999; 265: 501-523
4. Kuller LH, Tracy RP, Shaten J, Meilahn EN: Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol, 1996; 144: 537-547
5. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med, 1997; 336: 973-979
6. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH: Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation, 1998; 98: 731-733
7. Sato H, Miida T, Wada Y, Maruyama M, Murakami S, Hasegawa H, Kuroda T, Narita I, Nakano M, Gejyo F: Atherosclerosis is accelerated in patients with long-term well-controlled systemic lupus erythematosus (SLE). Clin Chim Acta, 2007; 385: 35-42
8. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW: Creactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol, 1999; 19: 972-978
9. Festa A, D'Agostino R Jr, Howard G, Mykkänen L, Tracy RP, Haffner SM: Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation, 2000; 102: 42-47
10. Kawamoto R, Tomita H, Inoue A, Ohtsuka N, Kamitani A: Impact of C-reactive protein on the likelihood of carotid atherosclerosis in Japanese adults. J Atheroscler Thromb, 2006; 13: 175-182
11. Ridker PM, Buring JE, Cook NR, Rifai N: C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation, 2003; 107: 391-397
12. Hanyu O, Miida T, Obayashi K, Ikarashi T, Soda S, Kaneko S, Hirayama S, Suzuki K, Nakamura Y, Yamatani K, Aizawa Y: Lipoprotein lipase (LPL) mass in preheparin serum reflects insulin sensitivity. Atherosclerosis, 2004; 174: 385-390
13. Hanyu O, Miida T, Kosuge K, Ito T, Soda S, Hirayama S, Wardaningsih E, Fueki Y, Obayashi K, Aizawa Y: Preheparin lipoprotein lipase mass is a practical marker of insulin resistance in ambulatory type 2 diabetic patients treated with oral hypoglycemic agents. Clin Chim Acta, 2007; 384: 118-123
14. Turner RC, Holman RR, Matthews D, Hockaday TD, Peto J: Insulin deficiency and insulin resistance interaction in diabetes: estimation of their relative contribution by feedback analysis from basal plasma insulin and glucose concentrations. Metabolism, 1979; 28: 1086-1096
15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 1985; 28: 412-419
16. Brinkmann GL, Coates EO Jr: The effect of bronchitis, smoking and occupation on ventilation. Ann Rev Respir Dis, 1963; 87: 684-693
17. Wellen KE, Hotamisligil GS: Inflammation, stress, and diabetes. J Clin Invest, 2005; 115: 1111-1119
18. Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science, 1993; 259: 87-91
19. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM: Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest, 1995; 95: 2409-2415
20. Bastard JP, Maachi M, Van Nhieu JT, Jardel C, Bruckert E, Grimaldi A, Robert JJ, Capeau J, Hainque B: Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab, 2002; 87: 2084-2089
21. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM: IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science, 1996; 271: 665-668
22. Senn JJ, Klover PJ, Nowak IA, Mooney RA: Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes, 2002; 51: 3391-3399
23. Rotter V, Nagaev I, Smith U: Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem, 2003; 278: 45777-45784
24. Mastorakos G, Chrousos GP, Weber JS: Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab, 1993; 77: 1690-1694
25. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V: Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link ? Atherosclerosis, 2000; 148: 209-214
26. Fueki Y, Miida T, Wardaningsih E, Ito M, Nakamura A, Takahashi A, Hanyu O, Tsuda A, Saito H, Hama H, Okada M: Regular alcohol consumption improves insulin resistance in healthy Japanese men independent of obesity. Clin Chim Acta, 2007; 382: 71-76
27. Campos SP, Baumann H: Insulin is a prominent modulator of the cytokine-stimulated expression of acute-phase plasma protein genes. Mol Cell Biol, 1992; 12: 1789-1797
28. Sidhu JS, Cowan D, Kaski JC: The effects of rosiglitazone, a peroxisome proliferator-activated receptorgamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol, 2003; 42: 1757-1763
29. Mohanty P, Aljada A, Ghanim H, Hofmeyer D, Tripathy D, Syed T, Al-Haddad W, Dhindsa S, Dandona P: Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab, 2004; 89: 2728-2735
30. Jarva H, Jokiranta TS, Hellwage J, Zipfel PF, Meri S: Regulation of complement activation by C-reactive protein: targeting the complement inhibitory activity of factor H by an interaction with short consensus repeat domains 7 and 8-11. J Immunol, 1999; 163: 3957-3962
31. Fukuchi Y, Miura Y, Nabeno Y, Kato Y, Osawa T, Naito M: Immunohistochemical detection of oxidative stress biomarkers, dityrosine and N(epsilon)-(hexanoyl)lysine, and C-reactive protein in rabbit atherosclerotic lesions. J Atheroscler Thromb, 2008; 15: 185-192
32. Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC: C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ, 1996; 312: 1061-1065
33. Burns DM: Cigarettes and cigarette smoking. Clin Chest Med, 1991; 12: 631-642
34. U.S. Department of Health E, and Welfare: The health consequences of smoking: a report to the surgeon general. DHEW Publication No 71-7513, Washington DC, US Department of Health, Education, and Welfare, Public Health Service 1971.
35. Haber J, Wattles J, Crowley M, Mandell R, Joshipura K, Kent RL: Evidence for cigarette smoking as a major risk factor for periodontitis. J Periodontol, 1993; 64: 16-23
36. Muscat JE, Harris RE, Haley NJ, Wynder EL: Cigarette smoking and plasma cholesterol. Am Heart J, 1991; 121:141-147
37. Campisi R, Czernin J, Schoder H, Sayre JW, Marengo FD, Phelps ME, Schelbert HR: Effects of long-term smoking on myocardial blood flow, coronary vasomotion, and vasodilator capacity. Circulation, 1998; 98: 119-125
38. Fusegawa Y, Goto S, Handa S, Kawada T, Ando Y: Platelet spontaneous aggregation in platelet-rich plasma is increased in habitual smokers. Thromb Res, 1999; 93:271-278
39. Bermudez EA, Rifai N, Buring JE, Manson JE, Ridker PM: Relation between markers of systemic vascular inflammation and smoking in women. Am J Cardiol, 2002; 89: 1117-1119
40. Facchini FS, Hollenbeck CB, Jeppesen J, Chen YD, Reaven GM: Insulin resistance and cigarette smoking. Lancet, 1992; 339: 1128-1130
41. Winternitz WW, Quillen D: Acute hormonal response to cigarette smoking. J Clin Pharmacol, 1977; 17: 389-397
42. Morrow JD, Frei B, Longmire AW, Gaziano JM, Lynch SM, Shyr Y, Strauss WE, Oates JA, Roberts LJ 2nd: Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med, 1995; 332: 1198-1203
43. Ross R: Atherosclerosis--an inflammatory disease. N Engl J Med, 1999; 340: 115-126